William J. John

TL;DR: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexing-cisplatin induction therapy.

TL;DR: This is the first report demonstrating that a vaccine therapy is capable of breaking "immune tolerance" to CEA in patients with CEA positive tumors.

TL;DR: Dose intensity of 5-FU and dose of radiation correlate significantly with the likelihood of achieving a pCR, and a preoperative radiation dose of 5500 cGy or higher can achieve pCR rates of approximately 50%, even in fixed cancers of the rectum.

TL;DR: CeaVac consistently generated a potent anti-CEA humoral and cellular immune response in all 32 patients entered onto this trial, and these data warrant a phase III trial for patients with resected colon cancer.

TL;DR: The measured energy expenditure per gram of creatinine was significantly increased in alcoholic hepatitis patients, supporting the concept of alcoholic hepatitis as a hypermetabolic state.